Real-World Evidence Studies

Early treatment with first-line CABLIVI significantly reduced unfavorable outcomes vs historical controls* during the very acute phase of aTTP in this real-world setting.²

Improved therapeutic outcomes were observed with CABLIVI used as first-line treatment vs historical controls* in patients with aTTP in a real-world setting.³

First-line CABLIVI treatment vs non–first-line CABLIVI in a real-world cohort of patients with aTTP was associated with improved outcomes.⁴

Improved outcomes were seen in most cohorts receiving CABLIVI treatment vs non-CABLIVI treatment in an aggregated analysis of RCTs and RWE.⁴ 

Patients treated with CABLIVI showed better clinical outcomes, with tendentially shorter hospital stays and lower mortality rates.⁵